Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD.
Article Details
- CitationCopy to clipboard
Donohue JF, Rheault T, MacDonald-Berko M, Bengtsson T, Rickard K
Ensifentrine as a Novel, Inhaled Treatment for Patients with COPD.
Int J Chron Obstruct Pulmon Dis. 2023 Jul 28;18:1611-1622. doi: 10.2147/COPD.S413436. eCollection 2023.
- PubMed ID
- 37533771 [ View in PubMed]
- Abstract
Ensifentrine is a novel, potent, and selective dual inhibitor of phosphodiesterase (PDE)3 and PDE4 designed for delivery by inhalation that combines effects on airway inflammation, bronchodilation and ciliary function in bronchial epithelia. In Phase 2 studies in subjects with COPD, ensifentrine demonstrated clinically meaningful bronchodilation and improvements in symptoms and health-related quality of life when administered alone or in combination with current standard of care therapies. Ensifentrine is currently in late-stage clinical development for the maintenance treatment of patients with COPD. This review summarizes non-clinical data as well as Phase 1 and Phase 2 efficacy and safety results of nebulized ensifentrine relevant to the maintenance treatment of patients with COPD.
DrugBank Data that Cites this Article
- Drugs
- Drug Targets
Drug Target Kind Organism Pharmacological Action Actions Ensifentrine Phosphodiesterase 3 (Protein Group) Protein group Humans YesInhibitorDetails Ensifentrine Phosphodiesterase 4 (Protein Group) Protein group Humans YesInhibitorDetails